HRP20120660T1 - Tekuće formulacije lh - Google Patents

Tekuće formulacije lh Download PDF

Info

Publication number
HRP20120660T1
HRP20120660T1 HRP20120660AT HRP20120660T HRP20120660T1 HR P20120660 T1 HRP20120660 T1 HR P20120660T1 HR P20120660A T HRP20120660A T HR P20120660AT HR P20120660 T HRP20120660 T HR P20120660T HR P20120660 T1 HRP20120660 T1 HR P20120660T1
Authority
HR
Croatia
Prior art keywords
formulation according
luteinizing hormone
concentration
formulation
hlh
Prior art date
Application number
HRP20120660AT
Other languages
English (en)
Croatian (hr)
Inventor
Agostinetto Rita
Samaritani Fabrizio
Del Rio Alessandra
Richard Joel
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of HRP20120660T1 publication Critical patent/HRP20120660T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HRP20120660AT 2007-11-01 2008-10-29 Tekuće formulacije lh HRP20120660T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
US448107P 2007-11-28 2007-11-28
PCT/EP2008/064679 WO2009056569A1 (en) 2007-11-01 2008-10-29 Lh liquid formulations

Publications (1)

Publication Number Publication Date
HRP20120660T1 true HRP20120660T1 (hr) 2012-09-30

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120660AT HRP20120660T1 (hr) 2007-11-01 2008-10-29 Tekuće formulacije lh

Country Status (25)

Country Link
US (1) US8664369B2 (enExample)
EP (1) EP2219607B1 (enExample)
JP (1) JP5551601B2 (enExample)
KR (1) KR101513181B1 (enExample)
CN (1) CN101842083B (enExample)
AU (1) AU2008320844B2 (enExample)
BR (1) BRPI0818324B8 (enExample)
CA (1) CA2700662C (enExample)
CY (1) CY1113121T1 (enExample)
DK (1) DK2219607T3 (enExample)
EA (1) EA019432B1 (enExample)
EC (1) ECSP10010224A (enExample)
ES (1) ES2393233T3 (enExample)
HR (1) HRP20120660T1 (enExample)
IL (1) IL205105A (enExample)
MX (1) MX2010004639A (enExample)
MY (1) MY153976A (enExample)
NZ (1) NZ583991A (enExample)
PL (1) PL2219607T3 (enExample)
PT (1) PT2219607E (enExample)
RS (1) RS52566B (enExample)
SI (1) SI2219607T1 (enExample)
UA (1) UA101484C2 (enExample)
WO (1) WO2009056569A1 (enExample)
ZA (1) ZA201001907B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2015006997A (es) * 2012-12-26 2015-09-23 Wockhardt Ltd Composicion farmaceutica.
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
CA2932873A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
DE69524456T2 (de) * 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
CA2335340C (en) * 1998-07-23 2013-03-05 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
ES2321297T3 (es) * 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular.
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
WO2004087213A1 (en) * 2003-04-02 2004-10-14 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant

Also Published As

Publication number Publication date
RS52566B (sr) 2013-04-30
BRPI0818324A2 (pt) 2017-05-16
CA2700662A1 (en) 2009-05-07
WO2009056569A1 (en) 2009-05-07
MY153976A (en) 2015-04-30
WO2009056569A9 (en) 2010-01-21
AU2008320844A1 (en) 2009-05-07
CN101842083A (zh) 2010-09-22
IL205105A0 (en) 2010-11-30
US8664369B2 (en) 2014-03-04
KR101513181B1 (ko) 2015-04-21
BRPI0818324B8 (pt) 2021-05-25
PL2219607T3 (pl) 2012-12-31
EA201070549A1 (ru) 2010-10-29
SI2219607T1 (sl) 2012-09-28
BRPI0818324B1 (pt) 2019-12-24
UA101484C2 (en) 2013-04-10
MX2010004639A (es) 2010-08-04
DK2219607T3 (da) 2013-06-17
CY1113121T1 (el) 2016-04-13
ECSP10010224A (es) 2010-07-30
CN101842083B (zh) 2012-11-14
EA019432B1 (ru) 2014-03-31
EP2219607B1 (en) 2012-08-15
JP2011502968A (ja) 2011-01-27
AU2008320844B2 (en) 2013-08-29
IL205105A (en) 2015-04-30
ZA201001907B (en) 2011-05-25
JP5551601B2 (ja) 2014-07-16
ES2393233T3 (es) 2012-12-19
CA2700662C (en) 2015-10-13
HK1145443A1 (en) 2011-04-21
PT2219607E (pt) 2012-08-31
US20100261649A1 (en) 2010-10-14
KR20100088147A (ko) 2010-08-06
EP2219607A1 (en) 2010-08-25
NZ583991A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
JP2011502968A5 (enExample)
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
HRP20200998T1 (hr) Postupak i sastav za liječenje okularne hipertenzije i glaukoma
HRP20210298T1 (hr) Dostava terapijskih agensa u središnji živčani sustav
ME01337B (me) Tečni preparat fsh
NZ629261A (en) Pharmaceutical formulations of tnf-alpha antibodies
HRP20191843T1 (hr) Mikobakterijski antigenski pripravak
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
US11162500B2 (en) Stable liquid formulation of AMG 416 (etelcalcetide)
RU2010121165A (ru) Составы паратиреоидного гормона и их применение
RU2407514C2 (ru) Водные композиции чфсг
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
JP2015527402A5 (enExample)
HRP20240635T1 (hr) Dugodjelujući hormoni rasta i postupci proizvodnje istog
PE20120204A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
AR040881A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-alfa
CO6150127A2 (es) Formulaciones de flibanserina y metodo para fabricarlas
RU2605288C2 (ru) Фармацевтическая композиция
JP2016539921A5 (enExample)
US20170189528A1 (en) Stable aqueous adalimumab formulation
JP2015531377A5 (enExample)
CN102821782B (zh) 促卵泡激素的液体配制品
WO2016038521A1 (en) Pharmaceutical compositions of liraglutide
HRP20200196T1 (hr) Fiziološki balansirane injektabilne formulacije fosnetupitanta
HRP20140676T1 (hr) Formulacije deoksikolne kiseline i njezinih soli